Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel agents on the response and outcomes. Three groups were established based on their cytogenetics: (1) t(11;14); (2) high-risk chromosomal abnormalities; and (3) standard risk (SR). After 80.1 months (1.2–273.8 months) of follow-up, no differences were observed in overall survival (OS) between the t(11;14) and SR groups (75.8 vs. 87.2 months; P = 0.438). Treatment of MM t(11;14) with novel agents did not improve their overall response rate (ORR) or complete response (CR) compared with those who received conventional therapy (ORR: 87.2 vs. 79.5%, P = 0.336; CR: 23.4 vs. 12.8%, P = 0.215). This effect translated into a similar PFS (39.6 vs. 30.0 months; P = 0.450) and OS (107.6 vs. 75.7 months; P = 0.175). In summary, MM t(11;14) patients did not benefit from the introduction of novel agents as much as SR patients did, indicating that other therapies are needed to improve their outcomes.
伴有t(11;14)异常的多发性骨髓瘤（MM）患者具有独特的生物学特征，其预后情况尚未明确。我们报告了一项针对591例MM患者的回顾性研究，其中17.3%存在t(11;14)异常。本研究旨在评估该染色体异常的预后影响，以及新型药物对治疗反应和临床结局的作用。根据细胞遗传学特征将患者分为三组：（1）t(11;14)组；（2）高风险染色体异常组；（3）标准风险组。经过平均80.1个月（范围1.2–273.8个月）的随访，t(11;14)组与标准风险组的总生存期无显著差异（75.8个月 vs 87.2个月；P=0.438）。与接受传统治疗的患者相比，使用新型药物治疗的t(11;14)患者的总缓解率和完全缓解率均未得到改善（总缓解率：87.2% vs 79.5%，P=0.336；完全缓解率：23.4% vs 12.8%，P=0.215）。这一结果体现为两组患者无进展生存期（39.6个月 vs 30.0个月；P=0.450）和总生存期（107.6个月 vs 75.7个月；P=0.175）均无显著差异。总之，t(11;14)异常MM患者未能像标准风险患者那样从新型药物中同等获益，表明需要探索其他治疗方案以改善其临床结局。
Multiple myeloma with t(11;14): impact of novel agents on outcome
肿瘤(癌症)患者之家